Skip to main content
Clinical Trials/JPRN-UMIN000048397
JPRN-UMIN000048397
Recruiting
N/A

A multicenter prospective study to evaluate the effect of elobixibat on spontaneous defecation without a feeling of residual stool in patients with chronic constipation who are inadequately effective with magnesium oxide, a first-line treatment for constipation. - A multicenter prospective study to evaluate the effect of elobixibat on spontaneous defecation without a feeling of residual stool in patients with chronic constipation who are inadequately effective with magnesium oxide, a first-line treatment for constipation.

Medical corporation Irisawa Medical Clinic0 sites26 target enrollmentJuly 18, 2022

Overview

Phase
N/A
Intervention
Not specified
Conditions
chronic constipation
Sponsor
Medical corporation Irisawa Medical Clinic
Enrollment
26
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 18, 2022
End Date
December 31, 2025
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Medical corporation Irisawa Medical Clinic

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\) Patients with a history of hypersensitivity to elobixibat 2\) Patients with confirmed or suspected intestinal obstruction due to tumor, hernia, etc. 3\) Patients suspected of having constipation due to organic disease 4\) Patients taking other laxatives 5\) Others who are judged by the principal investigator to be inappropriate as research subjects

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
N/A
arge cell D-type stents for patients with inoperable malignant hilar biliary obstructioNeoplasms
KCT0002198Ajou University Hospital40
Completed
N/A
Prospective multicenter Study to evaluate the Effect of tight and systematic monitoring by Ultrasound on Therapy and Outcome in Patients with early rheumatoid Arthritisrheumatoid arthritisM05Seropositive rheumatoid arthritis
DRKS00010485Charité Universitätsmedizin Berlin -Med. Klinik mit SP Rheumatologie und Klin. Immunologie453
Not Yet Recruiting
N/A
Multicenter randamized study for evaluating the effect of dantrolene aganst heart failure and arrhythmiaheart failure
JPRN-UMIN000022756Yamaguchi University Graduate School of Medicine100
Active, Not Recruiting
N/A
A multi-centre randomised study to evaluate the efficacy of Betaferon-interferon-beta-1b (IFNB-1B) 500 mcg therapy in the induction of tolerance to IFNB in MS patients with neutralising antibodies (NAbs) to IFNB-1a (Rebif) - Betaferon NaB Anergy StudyMultiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system of unknown aetiology. It is the commonest cause of disability in young adults. The prevalence in the UK is approximately 125/100,000 of the population with an annual incidence of 6/100,000. Approximately 80,000 individuals are affected with MS in the UK.
EUCTR2005-005751-18-GBCL Biomedicine R&D Unit100
Not Yet Recruiting
N/A
A Prospective randomized multi-center study for efficacy of metallic biliary stent compared to plastic stent in patients receiving neoadjuvant chemotherapy for resectable pancreatic cancer
KCT0006294Yonsei University Health System, Severance Hospital196